FDA approves Tevimbra combo for HER2+ gastric cancer treatment
We haven't written up this one. Investing.com has the full story — the link below goes straight to it.
This story
This is one outlet's version. Read the fullest account.
- FDA approves Jazz’s Ziihera for HER2+ gastric cancer treatment investing.com
- U.S. FDA Approves Ziihera® (zanidatamab-hrii) with and without Tislelizumab plus Chemotherapy in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma financialpost.com
- FDA approves Jazz's Ziihera in frontline gastric cancer endpoints.news
- Jazz wins FDA nod for cancer therapy developed with BeOne, Zymeworks seekingalpha.com
